Gadobenate dimeglumine as an intrabiliary contrast agent: Comparison with Mangafodipir trisodium with respect to non-dilated biliary tree depiction

Korean Journal of Radiology

Volumn 6, Issue 4, 2005, Pages 229-234

  Joon, Seok Lim ^a   Kim, Myeong Jin ^a   Yong, Yun Jung ^a   Ki, Whang Kim ^a  

^a Yonsei University College of Medicine   (South Korea)

Author keywords

Anatomy; Bile duct radiography; Bile ducts; Contrast media; Magnetic resonance (MR); Technology

Indexed keywords

CONTRAST MEDIUM; DIAGNOSTIC AGENT; DRUG DERIVATIVE; EDETIC ACID; GADOBENIC ACID; MEGLUMINE; N,N' BIS(PYRIDOXAL 5 PHOSPHATE)ETHYLENEDIAMINE N,N' DIACETIC ACID; N,N'-BIS(PYRIDOXAL-5-PHOSPHATE)ETHYLENEDIAMINE-N,N'-DIACETIC ACID; ORGANOMETALLIC COMPOUND; PYRIDOXAL 5 PHOSPHATE;

ADULT; AGED; ARTICLE; BILE DUCT; COMMON BILE DUCT; COMPARATIVE STUDY; FEASIBILITY STUDY; FEMALE; HEPATIC DUCT; HISTOLOGY; HUMAN; MALE; MIDDLE AGED; NUCLEAR MAGNETIC RESONANCE IMAGING;

ADULT; AGED; BILE DUCTS; COMMON BILE DUCT; CONTRAST MEDIA; EDETIC ACID; FEASIBILITY STUDIES; FEMALE; HEPATIC DUCT, COMMON; HUMANS; MAGNETIC RESONANCE IMAGING; MALE; MEGLUMINE; MIDDLE AGED; ORGANOMETALLIC COMPOUNDS; PYRIDOXAL PHOSPHATE;

EID: 31144446095     PISSN: 12296929     EISSN: 12296929     Source Type: Journal    
DOI: 10.3348/kjr.2005.6.4.229     Document Type: Article

References (23)

1. Takehara Y. Fast MR imaging for evaluating the pancreaticobiliary system. Eur J Radiol 1999;29:211-232
2. Irie H, Honda H, Tajima T, Kuroiwa T, Yoshimitsu K, Makisumi K, et al. Optimal MR cholangiopancreatographic sequence and its clinical application. Radiology 1998;206:379-387
3. Fulcher AS, Turner MA, Capps GW, Zfass AM, Baker KM. Half-Fourier RARE MR cholangiopancreatography: experience in 300 subjects. Radiology 1998;207:21-32
4. Choi JW, Kim TK, Kim KW, Kim AY, Kim PN, Ha HK, et al. Anatomic variation in intrahepatic bile ducts: an analysis of intraoperative cholangiograms in 300 consecutive donors for living donor liver transplantation. Korean J Radiol 2003;4:85-90
5. Hintze RE, Adler A, Veltzke W, Abou-Rebyeh H, Hammerstingl R, Vogl T, et al. Clinical significance of magnetic resonance cholangiopancreatography (MRCP) compared to endoscopic retrograde cholangiopancreatography (ERCP). Endoscopy 1997;29:182-187
6. Irie H, Honda H, Kuroiwa T, Yoshimitsu K, Aibe H, Shinozaki K, et al. Pitfalls in MR cholangiopancreatographic interpretation. Radiographics 2001;21:23-37
7. Mitchell DG, Alam F. Mangafodipir trisodium: effects on T2- and T1-weighted MR cholangiography. J Magn Reson Imaging 1999;9:366-368
8. Papanikolaou N, Prassopoulos P, Eracleous E, Maris T, Gogas C, Gourtsoyiannis N. Contrast-enhanced magnetic resonance cholangiography versus heavily T2-weighted magnetic resonance cholangiography. Invest Radiol 2001;36:682-686
9. Lee VS, Rofsky NM, Morgan GR, Teperman LW, Krinsky GA, Berman P, et al. Volumetric mangafodipir trisodium-enhanced cholangiography to define intrahepatic biliary anatomy. AJR Am J Roentgenol 2001;176:906-908
10. Carlos RC, Hussain HK, Song JH, Francis IR. Gadolinium-ethoxybenzyl- diethylenetriamine pentaacetic acid as an intrabiliary contrast agent: preliminary assessment. AJR Am J Roentgenol 2002;179:87-92
11. Kapoor V, Peterson MS, Baron RL, Patel S, Eghtesad B, Fung JJ. Intrahepatic biliary anatomy of living adult liver donors: correlation of mangafodipir trisodium-enhanced MR cholangiography and intraoperative cholangiography. AJR Am J Roentgenol 2002;179:1281-1286
12. Vitellas KM, El-Dieb A, Vaswani KK, Bennett WF, Fromkes J, Ellison C, et al. Using contrast-enhanced MR cholangiography with IV mangafodipir trisodium (Teslascan) to evaluate bile duct leaks after cholecystectomy: a prospective study of 11 patients. AJR Am J Roentgenol 2002;179:409-416
13. Kim KW, Park MS, Yu JS, Chung JP, Ryu YH, Lee SI, et al. Acute cholecystitis at T2-weighted and manganese-enhanced T1-weighted MR cholangiography: preliminary study. Radiology 2003;227:580-584
14. Marinelli ER, Neubeck R, Song B, Wagler T, Ranganathan RS, Sukumaran K, et al. Synthesis, characterization, and imaging performance of a new class of macrocyclic hepatobiliary MR contrast agents. Invest Radiol 2000;35:8-24
15. Kirchin MA, Pirovano GP, Spinazzi A. Gadobenate dimeglumine (Gd-BOPTA). An overview. Invest Radiol 1998;33:798-809
16. Lorusso V, Arbughi T, Tirone P, de Haen C. Pharmacokinetics and tissue distribution in animals of gadobenate ion, the magnetic resonance imaging contrast enhancing component of gadobenate dimeglumine 0.5 M solution for injection (MultiHance). J Comput Assist Tomogr 1999;23 Suppl 1:S181-194
17. Spinazzi A, Lorusso V, Pirovano G, Kirchin M. Safety, tolerance, biodistribution, and MR imaging enhancement of the liver with gadobenate dimeglumine: results of clinical pharmacologic and pilot imaging studies in nonpatient and patient volunteers. Acad Radiol 1999;6:282-291
18. Elizondo G, Fretz CJ, Stark DD, Rocklage SM, Quay SC, Worah D, et al. Preclinical evaluation of MnDPDP: new paramagnetic hepatobiliary contrast agent for MR imaging. Radiology 1991;178:73-78
19. Hamm B, Vogl TJ, Branding G, Schnell B, Taupitz M, Wolf KJ, et al. Focal liver lesions: MR imaging with Mn-DPDP-initial clinical results in 40 patients. Radiology 1992;182:167-174
20. Slater GJ, Saini S, Mayo-smith WW, Sharma P, Eisenberg PJ, Hahn PF. Mn-DPDP enhanced MR imaging of the liver: analysis of pulse sequence performance. Clin Radiol 1996;51:484-486
21. Wang C, Gordon PB, Hustvedt SO, Grant D, Sterud AT, Martinsen I, et al. MR imaging properties and pharmacokinetics of MnDPDP in healthy volunteers. Acta Radiol 1997;38(4 Pt 2):665-676
22. Reimer P, Schneider G, Schima W. Hepatobiliary contrast agents for contrast-enhanced MRI of the liver: properties, clinical development and applications. Eur Radiol 2004;14:559-578
23. Caudana R, Morana G, Pirovano GP, Nicoli N, Portuese A, Spinazzi A, et al. Focal malignant hepatic lesions: MR imaging enhanced with gadolinium benzyloxypropionictetra-acetate (BOPTA)-preliminary results of phase II clinical application. Radiology 1996;199:513-520